Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;20(2):197-209.
doi: 10.1080/1744666X.2023.2270737. Epub 2024 Jan 21.

A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons

Ecem Sevim  1 , Dale Kobrin  1 , Maria Casal-Dominguez  2   3 , Iago Pinal-Fernandez  2   3
Affiliations
Review

A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons

Ecem Sevim et al. Expert Rev Clin Immunol. 2024 Feb.

Abstract

Introduction: Dermatomyositis (DM) is a rare inflammatory disease with diverse cutaneous and systemic manifestations, often associated with myositis-specific antibodies. Managing patients with refractory DM, or individuals presenting pecific complications, like calcinosis or rapidly progressive interstitial lung disease, presents unique challenges.

Areas covered: This review explores current and promising treatment options for DM, drawing from clinical studies, case series, and case reports that consider the underlying disease pathophysiology.

Expert opinion: Recent advancements have improved our understanding and management of DM. The discovery of distinct DM autoantibodies and their correlation with specific clinical phenotypes has transformed patient categorization and enhanced our knowledge of the pathogenesis of the disease. Intravenous immunoglobulin, a well-established treatment in dermatomyositis, has regained prominence and a large randomized clinical trial has reaffirmed its efficacy, confirming it as an effective therapeutic option in this group of patients. Identification of the type I interferon pathway as a key pathogenic mechanism in DM has opened up new avenues for more effective treatment strategies. Blocking the JAK/STAT pathway offers potential for improved management of refractory patients and prevention of highly morbid complications. These recent advancements have significantly impacted the management and care of dermatomyositis patients, enabling tailored approaches, targeted interventions, and improved outcomes for individuals affected by this complex condition.

Keywords: Dermatomyositis; IVIG; JAK/STAT; autoantibodies; inflammatory myopathies.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Treatment mechanisms in Dermatomyositis. IL: Interleukin, TCR: T-Cell Receptor, TLR: Toll-like Receptor, MHC: Major Histocompatibility Complex, HCQ: Hydroxychloroquine, AZA: Azathioprine, MTX: Methotrexate, MMF: Mycophenolate, LEF: Leflunomide: CHLR: Chlorambucil. Not included in this figure: Adrenocorticotrophic Hormone Gel, Dapsone, Apremilast, Naltrexone, Lenabasum, Hematopoietic Stem Cell Transplantation
See this image and copyright information in PMC

References

    1. Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018. Sep;17(9):816–828. doi: 10.1016/S1474-4422(18)30254-0 - DOI - PMC - PubMed
    1. Casal-Dominguez M, Pinal-Fernández I, Mammen AL. Utility of myositis-specific autoantibodies for treatment selection in myositis. Curr Treat Options Rheumatology. 2022. Dec 01;8 (4):105–116.
    1. Casal-Dominguez M, Pinal-Fernandez I, Pak K, et al. Performance of the 2017 European alliance of associations for rheumatology/American college of rheumatology classification criteria for idiopathic inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis & Rheumat. 2022. Mar;74(3):508–517. doi: 10.1002/art.41964 - DOI - PMC - PubMed
    1. Van Gompel E, Demirdal D, Fernandes-Cerqueira C, et al. Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains. Rheumatology. 2023. doi: 10.1093/rheumatology/kead400 - DOI - PMC - PubMed
    1. Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, et al. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology. 2019. Nov 5;93(19):e1768–e1777. doi: 10.1212/WNL.0000000000008443 - DOI - PMC - PubMed

Publication types

LinkOut - more resources